A trial of Rigosertib for Pediatric RASopathies

Trial Profile

A trial of Rigosertib for Pediatric RASopathies

Planning
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Developmental disabilities
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2017 New trial record
    • 09 Nov 2017 This trial is expected to start next year at National Cancer Institute and will be funded by the NIH, as reported in an Onconova Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top